John Oyler - 10 Jun 2025 Form 4 Insider Report for BeOne Medicines Ltd. (ONC)

Role: Chief Executive Officer, Director
Signature: /s/ Qing Nian, as Attorney-in-Fact
Issuer symbol: ONC
Transactions as of: 10 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 12 Jun 2025, 17:38:04 UTC
Previous filing: 10 Jun 2025
Next filing: 18 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
OYLER JOHN	Chief Executive Officer, Director	C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, SWITZERLAND	/s/ Qing Nian, as Attorney-in-Fact	12 Jun 2025	0001042047

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ONC	Ordinary Shares	Award	$0	+185,055	+2.3%	$0.000000	8,281,841	10 Jun 2025	Direct	F1
holding	ONC	Ordinary Shares						481,533	10 Jun 2025	See Footnote	F2
holding	ONC	Ordinary Shares						7,722,480	10 Jun 2025	See Footnote	F3
holding	ONC	Ordinary Shares						28,204,115	10 Jun 2025	See Footnote	F4
holding	ONC	Ordinary Shares						9,545,000	10 Jun 2025	See Footnote	F5
holding	ONC	Ordinary Shares						102,188	10 Jun 2025	See Footnote	F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ONC	Share Option (Right to Buy)	Award	$0	+348,374		$0.000000	348,374	10 Jun 2025	Ordinary Shares	348,374	$20.26	Direct	F7, F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 10, 2025, subject to continued service. Unvested securities are subject to accelerated vesting upon a change of control or certain termination events.
F2	These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership.
F3	These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
F4	These securities are held by Oyler Investment LLC, of which 99% of the the limited liability company interest owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
F5	These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account.
F6	These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's minor child, for which the Reporting Person disclaims beneficial ownership.
F7	The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.
F8	These securities vest over a four-year period as follows: 25% on the first anniversary of June 10, 2025 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon a change of control or certain termination events.